A controlled and sustained local gentamicin delivery system for inner ear applications

Area of Science:

• Otolaryngology
• Drug Delivery Systems
• Inner Ear Therapeutics

Background:

• Intratympanic gentamicin injection (ITGI) is a common treatment for Ménière's disease.
• Patient variability in ITGI efficacy may stem from inconsistent drug diffusion.
• Sustained gentamicin delivery could improve treatment outcomes.

Purpose of the Study:

• To evaluate a novel hydrogel system for sustained gentamicin delivery to the inner ear.
• To compare the pharmacokinetic and functional effects of hydrogel-based gentamicin versus ITGI.
• To assess the potential of this system as an improved treatment for Ménière's disease.

Main Methods:

• In vivo study in mice comparing hydrogel-loaded gentamicin with ITGI.
• Analysis of gentamicin pharmacokinetics, hearing function, and balance function.
• Evaluation of drug release profiles over a 7-day period.

Main Results:

• The hydrogel system demonstrated sustained gentamicin release over 7 days, with a plateau from Day 1-3.
• ITGI showed rapid gentamicin clearance, with minimal drug levels by Day 3.
• Hydrogel delivery caused balance dysfunction but no significant hearing changes, unlike ITGI at the same dose.

Conclusions:

• The hydrogel system offers more sustained, consistent, and efficient gentamicin release than ITGI.
• This hydrogel system represents a promising new approach for treating Ménière's disease.
• Improved drug delivery may lead to more predictable therapeutic effects.